Surojit Mandal

Surojit Mandal

Auto-generated profile, based on publicly available information

Surojit Mandal

Non-Coding RNA and Cancer Biology Laboratory, Department of Zoology, Central University of Punjab, Bathinda, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2024 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
RYRitu Yadav
Ritu Yadav
RKRinku Khatkar
Rinku Khatkar
KYKenneth C-H Yap
Kenneth C-H Yap
CKChloe Yun-Hui Kang
Chloe Yun-Hui Kang
JLJuncheng Lyu
Juncheng Lyu
AJAklank Jain
Aklank Jain
Lung cancer is a severe challenge to the health care system with intrinsic resistance to first and second-line chemo/radiotherapies. In view of the sterile environment of lung cancer, several immunotherapeutic drugs including nivolumab, pembrolizumab, atezolizumab, and durvalumab are currently being used in clinics globally with the intention of releasing exhausted T-cells back against refractory tumor cells. Immunotherapies have a limited response rate and may cause immune-related adverse events (irAEs) in some patients. Hence, a deeper understanding of regulating immune checkpoint interactions could significantly enhance lung cancer treatments. In this review, we explore the role of miRNAs in modulating immunogenic responses against tumors. We discuss various aspects of how manipulating these checkpoints can bias the immune system’s response against lung cancer. Specifically, we examine how altering the miRNA profile can impact the activity of various immune checkpoint inhibitors, focusing on the PD-1/PD-L1 pathway within the complex landscape of lung cancer. We believe that a clear understanding of the host’s miRNA profile can influence the efficacy of checkpoint inhibitors and significantly contribute to existing immunotherapies for lung cancer patients. Additionally, we discuss ongoing clinical trials involving immunotherapeutic drugs, both as standalone treatments and in combination with other therapies, intending to advance the development of immunotherapy for lung cancer.

1 September 2023 in Biomarkers in Medicine
Verified
Journal Article
Closed access
AMAdrija Mohanta
Adrija Mohanta
RKRajiv R Kumar
Rajiv R Kumar
RSRahul K Singh
Rahul K Singh
SMSurojit Mandal
Surojit Mandal
RYRitu Yadav
Ritu Yadav
AJAklank Jain
Aklank Jain
A specialized biomarker(s) for lung cancer is imperative owing to its high mortality. Continuing our earlier work demonstrating the role of miR-320a as a tumor suppressor, here we discuss the most ...